Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01306201 · ClinicalTrials.gov registry record
Novel Non-Invasive Monitoring Parameter in a Hospital Setting
A clinical trial, sponsored by Medtronic - MITG.
- Completed
- Registry status
- 63
- Enrollment target
NCT01306201: Completed study, sponsored by Medtronic - MITG.
NCT01306201 is a clinical trial that has completed, run by Medtronic - MITG. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01306201 has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
Study Summary
Data collected from this study will be used to evaluate the performance of a monitoring algorithm.
Primary Outcome
Mean and standard deviations of respiration rates collected from patients in the hospital settings were compared between Covidien Respiration Rate Software, Transthoracic Impedance and End-Tidal Carbon Dioxide Waveforms. Each patient served as its own control.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-03 |
What the finished NCT01306201 record still lists
NCT01306201 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01306201 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01306201 about?
NCT01306201 is a clinical study titled "Novel Non-Invasive Monitoring Parameter in a Hospital Setting". Data collected from this study will be used to evaluate the performance of a monitoring algorithm.
What is the current status of trial NCT01306201?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2011-02. Estimated completion is 2012-03.
Who is sponsoring clinical trial NCT01306201?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia